ライフサイエンスコーパス: calcitriol

1 abolite of vitamin D(3), into 1,25(OH)2D(3) (calcitriol).

2 ecomes more severe, limiting the efficacy of calcitriol.

3 corrected with phosphate supplementation and calcitriol.

4 fore influences the efficacy of therapy with calcitriol.

5 vitamin D receptor only about 1% as well as calcitriol.

6 sed to assess the antiangiogenic activity of calcitriol.

7 mall interfering RNA restored sensitivity to calcitriol.

8 be significant bone loss after discontinuing calcitriol.

9 tor but declined with daily and intermittent calcitriol.

10 ed media of prostate cancer cells exposed to calcitriol.

11 d, although these changes were attenuated by calcitriol.

12 ate width did not increase with either GH or calcitriol.

13 nt survival advantage over those who receive calcitriol.

14 cription factor mediating genomic actions of calcitriol.

15 cells and makes T cells highly sensitive to calcitriol.

16 to its DNA target sequences was enhanced by calcitriol.

17 the only miRNA significantly up-regulated by calcitriol.

18 scription in the nanomolar range, similar to calcitriol.

19 and neonate without relying on vitamin D or calcitriol.

20 Very low doses of calcitriol (0.1-1 mug/kg body weight) were sufficient to

21 h quarterly 2 mg IBN intravenously and daily calcitriol (0.25-1.0 mug) on top of 1000 mg calcium and

22 Thirty-seven patients were treated with oral calcitriol (0.5 micro g/kg) on day 1 followed by docetax

23 eceive either alendronate (10 mg per day) or calcitriol (0.5 microg per day) a mean (+/-SD) of 21+/-1

24 re at least as antiproliferative in vitro as calcitriol (1) even at physiologically relevant low nano

25 3b and oxime ether 4b, analogues of natural calcitriol (1), were rationally designed and synthesized

26 onsiderably less calcemic (i.e., safer) than calcitriol (1).

27 one 2b is more transcriptionally potent than calcitriol (1).

28 0% of the transcriptional potency of natural calcitriol (1).

29 Calcitriol (1,25-dihydroxycholecalciferol), the major ac

30 Calcitriol (1,25-dihydroxycholecalciferol), the most act

31 s to evaluate the antiangiogenic activity of calcitriol (1,25-dihydroxyvitamin D(3)) in vivo and its

32 Oral calcitriol (1,25-dihydroxyvitamin D(3)) prevented as wel

33 Exogenous calcitriol (1,25-dihydroxyvitamin D) and high circulatin

34 phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skele

35 re were striking elevations in serum PTH and calcitriol [1,25-dihydroxyvitamin D] in subjects consumi

36 In all, 75 subjects (34 alendronate, 25 calcitriol, 16 reference) participated.

37 The A-rings of calcitriol (1alpha,25-dihydroxyvitamin D(3)) and 1alpha-

38 Calcitriol (1alpha,25-dihydroxyvitamin D3) is the active

39 We investigated the effects of calcitriol (1alpha,25-dihydroxyvitamin D3; the active fo

40 Furthermore, ingestion of calcitriol (1alpha25VitD3) by human volunteers led to an

41 were randomized to receive a single dose of calcitriol (2 mug intravenously) versus placebo.

42 study demonstrates that upon treatment with calcitriol, 24-hydroxylase (CYP24) mRNA, protein and enz

43 lcium (1200 mg/d), magnesium (550 mg/d), and calcitriol (25 mug/d) given either RCE (60 mg isoflavone

44 re measured through thin and thick layers of calcitriol 3 microg per g ointment and vehicle.

45 tment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001.

46 re assigned randomly to groups given 0.5 mug calcitriol, 75 mg acetylsalicylic acid, and 1250 mg calc

47 to 1alpha,25-dihydroxyvitamin D3 (1,25-D3 or calcitriol), a naturally occurring VDR agonist, VDR 4-1

48 Calcitriol, a regulator of calcium homeostasis with anti

49 Calcitriol, acting through vitamin D receptors (VDR) in

50 gical actions constitutes a novel pathway of calcitriol action that may contribute to its antiprolife

51 we present evidence that vitamin D hormone (calcitriol) activates the transcription of the serotonin

52 oidal analogues have been developed to mimic calcitriol activity profiles with low calcium serum leve

53 Calcitriol administration did not increase plasma cathel

54 Although no deaths occurred, calcitriol administration was associated with increased

55 ol but were slightly diminished during daily calcitriol administration.

56 In addition, calcitriol allows for the up-regulation of the recently

57 In these experiments, calcitriol alone had no effect on the HCV life cycle.

58 Calcitriol also augmented the angiogenic capacity of MAC

59 Calcitriol also repressed the mRNA expression of the PG

60 Calcitriol also up-regulated the expression of 15-hydrox

61 Since the calcitriol analogue 12 was prone to conversion into its

62 We demonstrate here that the calcitriol analogue, EB1089, extensively inhibits the gr

63 signed and synthesized novel C-9 substituted calcitriol analogues, possessing different nonpolar grou

64 is the use of 1alpha,25-dihydroxyvitamin D3 (calcitriol) analogues to inhibit cancer growth.

65 l death was significantly different for both calcitriol and 16,23-D(3) compared with control tumors a

66 synthesized two gemini which are related to calcitriol and 19-norcalcitriol containing two identical

67 d analogs are as transcriptionally active as calcitriol and are strongly antiproliferative in vitro b

68 ry low postoperative PTH levels require oral calcitriol and calcium supplementation.

69 t1, which was released upon stimulation with calcitriol and IFN-alpha.

70 We propose that a combination of calcitriol and nonselective NSAIDs might be a useful che

71 ude that low, clinically relevant dosages of calcitriol and paricalcitol may protect against CKD-stim

72 we studied the effects of the VDR activators calcitriol and paricalcitol on aortic calcification in a

73 plicated by the adynamic bone disorder; both calcitriol and paricalcitol stimulated osteoblast surfac

74 nt to correct secondary hyperparathyroidism, calcitriol and paricalcitol were protective against aort

75 te a small therapeutic effect of calcium and calcitriol and suggest that tacrolimus is less osteotoxi

76 le bovine blood was injected with 0.6 microg calcitriol and was dialyzed against 5 L of acetate-based

77 The combination of weekly oral high-dose calcitriol and weekly docetaxel is a well-tolerated regi

78 c ultraviolet modalities on the stability of calcitriol and, conversely, to study the effects of calc

79 mbination of acetylsalicylic acid (aspirin), calcitriol, and calcium carbonate could prevent colorect

80 atients were cultured with and without 10 nM calcitriol, and function determined by migration and ang

81 leted the randomized trial on alendronate or calcitriol, and in reference subjects who had received n

82 he 0.7- and 0.8-g/kg diets, midmolecule PTH, calcitriol, and nephrogenous cyclic adenosine monophosph

83 an associated increase in FGF23, decrease in calcitriol, and no change in phosphorus.

84 n VSMCs is upregulated by various retinoids, calcitriol, and T(3) in vitro; and (3) administration of

85 es, 25(OH)D, parathyroid hormone, estradiol, calcitriol, and urinary calcium at baseline and 6 wk in

86 Thus, calcitriol appears to suppress autoimmunity by inhibitin

87 These actions of calcitriol are mediated at least in part by vitamin D re

88 s, such as TNF-alpha, IFN-gamma, and LPS, or calcitriol, are not effective.

89 trials investigating the dose and timing of calcitriol as a therapeutic agent in specific sepsis phe

90 In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not preve

91 hibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydrox

92 Active VitD (calcitriol) blocked LEC tube formation, reduced LEC prol

93 After discontinuing alendronate or calcitriol, BMD remained stable during the second year a

94 -fed control group and the CKD low-phosphate/calcitriol/BMP-7 groups had reduced phosphate levels com

95 increased with GH alone or with intermittent calcitriol but were slightly diminished during daily cal

96 )D3 were independent predictors of decreased calcitriol, but the effects on calcitriol levels of rena

97 The endogenous production of calcitriol by monophosphoryl lipid A-stimulated DCs appe

98 ral hormone 1alpha,25-dihydroxyvitamin D(3) (calcitriol) by a 1alpha-CHF(2) group and incorporating a

99 ith blood was performed to determine whether calcitriol (Calcijex) is either bound or removed from bl

100 FGF-23, PTH, 25(OH)D3, calcitriol, calcium, phosphate, and urinary fractional e

101 ion that the intracellular concentrations of calcitriol can play an important role in either promotin

102 Oral calcitriol, compared with placebo, therapy of the patien

103 Finally, supernatants of calcitriol-conditioned bone marrow-derived DC had reduce

104 Although calcitriol corrects the malabsorption of calcium, it rem

105 Calcitriol (CTR) administration prevented a decrease in

106 m, monocytes treated with IFNgamma/TNFalpha/ calcitriol (CytD) were permissive for the growth of viru

107 per d (Nx-Phos+GH; n = 9), (3) GH and daily calcitriol (D) at 50 ng/kg per d (Nx-Phos+GH+daily D; n

108 iological or pharmacological doses of either calcitriol (D3) or a synthetic vitamin D2 analogue (19-n

109 in the face of advancing CKD but may worsen calcitriol deficiency and thus may be a central factor i

110 Hyperphosphatemia, calcitriol deficiency, and secondary hyperparathyroidism

111 eased fractional excretion of phosphate, and calcitriol deficiency.

112 ssociated with serum phosphate, Fe(PO4), and calcitriol deficiency.

113 preclinical proof of concept, we showed that calcitriol, delivered topically or intraperitoneally, in

114 It was shown that gemini, the calcitriol derivative containing two side chain at C20,

115 Moreover calcitriol or calcitriol derivatives combined with ITZ might be a trea

116 DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel wi

117 In vitro, calcitriol directly suppressed IL-17 induction in purifi

118 selectively and specifically altered BODIPY-calcitriol distribution.

119 vels, cinacalcet use, or phosphate binder or calcitriol dose in either study arm.

120 One trial that used a calcitriol dose of 0.5 microgram/d noted a fall in CCr a

121 found that pretreatment with Dex potentiates calcitriol effects by inhibiting cell growth and increas

122 To investigate the role of VDR in calcitriol effects on tumor vasculature, we established

123 However, calcitriol enhanced the inhibitory effect of IFN-alpha o

124 criptional potency almost as high as that of calcitriol, even though it binds to the human vitamin D

125 Calcitriol exhibits antiproliferative and pro-differenti

126 of 42 strata examined, and in no stratum was calcitriol favored.

127 The sham-operated low-phosphate/calcitriol-fed control group and the CKD low-phosphate/c

128 cipants in a trial comparing alendronate and calcitriol for prevention of posttransplant osteoporosis

129 randomized trial comparing alendronate with calcitriol for the prevention of bone loss during the fi

130 ibits 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; calcitriol) formation and phosphate reabsorption in the

131 E production and that B cells can synthesize calcitriol from its precursor 25-hydroxyvitamin D3 (inac

132 hat Ptch expression is sufficient to release calcitriol from the cell and that calcitriol inhibits Sm

133 ol was administered in the CKD low-phosphate/calcitriol group (ABD), Ca, PO(4), and parathyroid hormo

134 ne formation marker, increased by 54% in the calcitriol group (P< or =0.001) and by 32% in the alendr

135 ker, serum N-telopeptide, rose by 27% in the calcitriol group (P< or =0.001).

136 h 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001).

137 the alendronate group and 1.6 percent in the calcitriol group (P=0.25 for the test of no difference).

138 the alendronate group and 2.1 percent in the calcitriol group (P=0.69).

139 veloped in 27 percent of the patients in the calcitriol group and 7 percent of those in the alendrona

140 te group; P=0.15 for the comparison with the calcitriol group), and the mean density at the femoral n

141 in the alendronate group, 3.6 percent in the calcitriol group, and 13.6 percent in the reference grou

142 biochemical marker of bone resorption in the calcitriol group.

143 f CYP24, which led to loss of sensitivity to calcitriol growth inhibitory effects.

144 rgeted therapies under investigation include calcitriol, growth factor-targeted agents, epothilones a

145 Calcitriol had no effect on clinical outcomes nor were a

146 itamin D(3) and 1, 25-dihydroxyviatmin-D(3) (calcitriol) had beneficial effects in EAE/MS.

147 We conclude that endogenous calcitriol has an impact on the regulation of IgE in viv

148 Vitamin D and calcium are ineffective, but calcitriol has utility in some reports.

149 form of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), has a profound inhibitory effect on the dev

150 argylic ether analogs of the natural hormone calcitriol have been rationally designed and easily synt

151 Using BODIPY-calcitriol, here we monitored the subcellular distributi

152 d that subjects randomized to alendronate or calcitriol immediately after cardiac transplantation sus

153 In this small experimental study, calcitriol improved endothelial function in patients wit

154 7 inhibited the tumor suppressive effects of calcitriol in cultured colorectal cancer cells and in mi

155 underpin the beneficial clinical effects of calcitriol in patients with SR asthma by directing the S

156 n shown to increase the antitumor effects of calcitriol in squamous cell carcinoma.

157 as lead compound a 20(R) gemini, related to calcitriol in terms of it is A-ring, where one side chai

158 s increase was statistically significant for calcitriol in the time frame examined, but not statistic

159 uring MAC differentiation and that in vitro, calcitriol increased differentiation of monocytes into M

160 Treatment of primary osteoblasts with 10 nM calcitriol increased meltrin beta expression more than 3

161 We recently showed that calcitriol increases oxidative and inflammatory stress;

162 Calcitriol induced expression of miR-627, which down-reg

163 nimals and that was ascribed to the LOV- and calcitriol-induced immunomodulatory synergy.

164 A calcitriol-induced reduction of tubular creatinine secre

165 FRET also revealed that calcitriol induces formation of multiple nuclear foci of

166 Our earlier studies suggested that calcitriol induces translocation of cytoplasmic VDR, but

167 to release calcitriol from the cell and that calcitriol inhibits Smo action and ciliary translocation

168 n D, 1alpha,25-dihydroxyvitamin D3 (1,25D3) (calcitriol), into the third ventricle of the brain impro

169 ical steps in the synthesis of the A-ring of calcitriol involved an asymmetric carbonyl-ene reaction

170 it has been known for a number of years that calcitriol is a potent inhibitor of adipogenesis in this

171 These data suggest calcitriol is a potent inhibitor of retinal neovasculari

172 Calcitriol is implicated in many cellular functions incl

173 As the half-life of calcitriol is short, we hypothesized that there would be

174 gic vitamin D receptor agonist, 1,25(OH)2D3 (calcitriol), is synthesized by the essential enzyme 25-h

175 mone (PTH); and is associated with decreased calcitriol levels independent of renal function, hyperph

176 the hypophosphatemia and inappropriately low calcitriol levels observed after kidney transplantation

177 of decreased calcitriol, but the effects on calcitriol levels of renal function itself and hyperphos

178 ssociated with estimated GFR (eGFR), whereas calcitriol levels were linearly associated with eGFR.

179 mone (PTH) (>65 pg/ml), and 91.2% had normal calcitriol levels.

180 pite high parathyroid hormone (PTH) and high calcitriol levels.

181 ar mechanism by which the unliganded VDR and calcitriol-liganded VDR regulate adipogenesis.

182 These results indicate that calcitriol-mediated antiproliferative effects on TDEC ar

183 silencing of CYP24 contributes to selective calcitriol-mediated growth inhibition in endothelial cel

184 e were relatively resistant, suggesting that calcitriol-mediated growth inhibition on TDEC is VDR-dep

185 This effect was based on a calcitriol-mediated increase of IFN-alpha-induced gene e

186 se inhibitor 5-aza-2'-deoxycytidine restored calcitriol-mediated induction of CYP24, which led to los

187 ate retention, and its effect on calcium and calcitriol metabolism, in addition to roles played by me

188 In response to locally produced calcitriol, myeloid dendritic cells (DCs) migrated from

189 Patients randomized to calcitriol (n = 36) versus placebo (n = 31) had similar

190 In contrast, in vivo treatment with calcitriol of mice challenged for EAU impaired commitmen

191 Calcitriol ointment 3 microg per g was irradiated with 1

192 smission of ultraviolet A is reduced through calcitriol ointment and its vehicle by 17%-31% and 17%-4

193 Calcitriol ointment has been approved for the treatment

194 More than 90% of calcitriol ointment is degraded upon exposure to ultravi

195 iol and, conversely, to study the effects of calcitriol ointment on transmission of different forms o

196 When used in conjunction with phototherapy, calcitriol ointment should be applied after ultraviolet

197 67%-87% through vehicle and 50%-83% through calcitriol ointment.

198 d the effect of discontinuing alendronate or calcitriol on bone loss and biochemical markers of bone

199 The effects of calcitriol on expression of miR-627 and cell proliferati

200 knock-down reversed the inhibitory effect of calcitriol on LEC tube formation, demonstrating how such

201 The effects of calcitriol on retinal EC proliferation, migration, and c

202 The influences of locally produced calcitriol on the migration of activated DCs from sites

203 is combination therapy with low dose IBN and calcitriol on top of calcium and vitamin D supplementati

204 of low dose parenteral ibandronate (IBN) and calcitriol on top of calcium and vitamin D supplementati

205 l (control group) or the vitamin D analogues calcitriol or 1,25-dihydroxy-16-ene-23-yne vitamin D(3)

206 Actual use of the active form of vitamin D (calcitriol or 1alpha,25-dihydroxyvitamin D(3)) to treat

207 to 60 ml/min), the active vitamin D sterols calcitriol or alfacalcidol [1 alpha-hydroxyvitamin D3] h

208 ies and five major open-labeled studies with calcitriol or alfacalcidol are reviewed.

209 e improved and sometimes normalized by using calcitriol or alfacalcidol in daily doses of 0.25 to 0.5

210 Moreover calcitriol or calcitriol derivatives combined with ITZ m

211 Pharmacokinetics of either calcitriol or docetaxel were not affected by the presenc

212 itant with either intermittent doses of oral calcitriol or doxercalciferol for 8 mo, when bone biopsi

213 are severely vitamin D deficient or who lack calcitriol or its receptor.

214 asthma were subsequently randomized to oral calcitriol or placebo therapy, and identical studies wer

215 calcifediol or dihydroxycholecalciferols or calcitriol or vitamin D/aa[analogs & derivates] or ergoc

216 ant were randomized to calcium, calcium plus calcitriol, or placebo.

217 0.223 per person-year) among those receiving calcitriol (P<0.001).

218 mone (P<0.001) and a significant increase in calcitriol (P=0.02) were noted postengraftment.

219 mong those who switched from paricalcitol to calcitriol (P=0.04).

220 lices by mouse marrow cultures stimulated by calcitriol, parathyroid hormone, and basic-fibroblast gr

221 In contrast, levels of calcium, phosphorus, calcitriol, parathyroid hormone, or fibroblast growth fa

222 rming this indirect effect included elevated calcitriol, phosphorus, alkaline phosphatase, and recept

223 receptor (VDR) and its ligand 1,25-OH2-VD3 (calcitriol) play an essential role in mineral homeostasi

224 the cumulative dose of phosphate binders and calcitriol predicted abnormal vascular structure and fun

225 Calcitriol-pretreated tumors underwent enhanced apoptoti

226 blind study to determine whether calcium and calcitriol prevents posttransplant bone loss.

227 Moreover, the increased calcitriol produced in response to low-calcium diets sti

228 sphaturia on a per-nephron basis and inhibit calcitriol production, thereby contributing centrally to

229 Fibroblast growth factor (FGF) 23 inhibits calcitriol production, which could exacerbate calcium de

230 udies with paricalcitol and two studies with calcitriol) providing data for 688 patients were include

231 Calcitriol reduced IP-10 expression by MACs (p<0.0006),

232 Further, we confirmed that vitamin D (calcitriol) reduced calcification as measured by Alizari

233 y prostatic epithelial cells and showed that calcitriol regulated the expression of genes involved in

234 Together, we suggest that calcitriol represents a possible endogenous transmitter

235 Our data show that calcitriol represses the expression of BATF, a transcrip

236 The concentration of calcitriol required to inhibit retinal EC proliferation

237 The active form of vitamin D (calcitriol) restored the SLE MAC phenotype towards that

238 Treatment with calcitriol resulted in growth inhibition in TDEC express

239 At a lower concentration of calcitriol, retinal EC capillary morphogenesis in solubi

240 istration of the active vitamin D metabolite calcitriol reversed all these effects.

241 Calcitriol significantly repressed the mRNA and protein

242 During the neonatal period, calcitriol-stimulated intestinal calcium absorption beco

243 It inhibits bone resorption by calcitriol-stimulated mouse marrow cultures.

244 After calcitriol stimulation, we identified 2776 genomic posit

245 Moreover calcitriol strongly synergizes with itraconazole (ITZ) i

246 ence of normal serum levels of calcidiol and calcitriol suggests vitamin D resistance and deserves fu

247 se of routine vs. selective oral calcium and calcitriol supplementation found that routine supplement

248 that routine postoperative oral calcium and calcitriol supplementation results in lower rates of tet

249 The role of endogenous calcitriol synthesis for the regulation of IgE has not b

250 clastogenesis, and indirectly, by increasing calcitriol synthesis.

251 The combination of GH and calcitriol that is frequently used in children with rena

252 Calcitriol, the active form of vitamin D, in combination

253 tially neutralizing the antitumor effects of calcitriol, the active form of vitamin D.

254 In this article, we report that calcitriol, the active form of vitamin D3, can be admini

255 Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is

256 cium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D.

257 In contrast, in the absence of calcitriol, the unliganded VDR appears necessary for lip

258 In the presence of calcitriol, the VDR blocks adipogenesis by down-regulati

259 Nx-Calcium, n = 10), (c) received short-term calcitriol therapy (Nx-D, n = 10), or (d) nephrectomized

260 taining phosphate binding agents, aggressive calcitriol therapy, and parathyroidectomy.

261 severe form of SH and the most resistant to calcitriol therapy, higher TGF-alpha activation of the E

262 or fed low-phosphate chow supplemented with calcitriol to maintain normophosphatemia in CKD.

263 rvival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared w

264 r administration of 1,25-dihydroxyvitamin D (calcitriol) to critically ill patients with sepsis would

265 Calcitriol-treated animals demonstrated a significant de

266 lar level of VEGF was similar in control and calcitriol-treated animals.

267 Media from calcitriol-treated MACs more strongly attenuated TNFalph

268 Media from calcitriol-treated MACs significantly increased angiogen

269 scularization was significantly inhibited in calcitriol-treated mice.

270 the spine and hip was reported after 1 yr in calcitriol-treated patients compared with results in the

271 Calcitriol-treated patients had higher cathelicidin (P =

272 ring the serum and urinary calcium levels in calcitriol-treated patients makes alendronate more attra

273 clinical response to oral glucocorticoids in calcitriol-treated patients with SR asthma.

274 ong paricalcitol-treated patients than among calcitriol-treated patients.

275 Neither SLC20A1 nor XPR1 were affected by calcitriol treatment and remained suppressed.

276 Calcitriol treatment attenuated PG-mediated functional r

277 ts and the effect on immunophenotype of oral calcitriol treatment because it has been previously show

278 ion of TNF-alpha in tumors preconditioned by calcitriol treatment before receiving ALA-PDT.

279 While calcitriol treatment did not decrease cell proliferation

280 ells in vitro, an effect further enhanced by calcitriol treatment of SLE MACs.

281 Cells incubated with calcitriol under calcifying conditions specifically main

282 ism, and the absence of hypercalcemia before calcitriol use and then were matched by age and estimate

283 In conclusion, oral calcitriol use is associated with lower mortality in non

284 roid hormone, calcium, and phosphorous, oral calcitriol use was associated with a 26% lower risk for

285 Calcitriol use was associated with a greater risk for hy

286 We evaluated associations of oral calcitriol use with mortality and dialysis dependence in

287 Incident calcitriol users and nonusers were selected on the basis

288 rinary kidney injury markers were similar in calcitriol- versus placebo-treated patients (P > 0.05 fo

289 mulated in the presence of dexamethasone and calcitriol (vitamin D3).

290 When dietary phosphorus was restricted and calcitriol was administered in the CKD low-phosphate/cal

291 Calcitriol was associated with a higher risk of hypercal

292 Responsiveness to calcitriol was essential to promote the trafficking of m

293 The A-ring (Z)-dienol of calcitriol was synthesized in 12 steps from 3-(tert-buty

294 ith supplementation (calcium, magnesium, and calcitriol) was more effective than supplementation alon

295 ion and serum 1 alpha,25-dihydroxyvitamin D (calcitriol) were significantly lower in women living in

296 response to avoid a subsequent reduction in calcitriol, which could exacerbate hypocalcemia.

297 inflammatory stress; moreover, inhibition of calcitriol with high-calcium diets decreased both adipos

298 The association of calcitriol with improved survival was not statistically

299 The combination of calcitriol with nonsteroidal anti-inflammatory drugs (NS

300 posed to bioactive 1,25-dihydroxyvitamin D3 (calcitriol) with or without IFN-alpha.